Previous studies displayed PXR activation playing a key role in cancer drug resistance (Gupta et al., 2008; Mani et al., 2013) as well as conflicting evidence about PXR agonists causing tumor aggressiveness (Wang et al., 2011; Mani et al., 2013; Pondugula et al., 2016). Here, NR1I2 is linked to neoplasm.